Report on Novartis Limited Bangladesh (Part-1) - Assignment Point
Report on Novartis Limited Bangladesh (Part-1)
Subject: Entrepreneurship Development | Topics: ,


1.1: Overview of Novartis Limited:

Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number one in revenues, which accounted over $53 billion in 2008, and number three in sales, which accounted 36.172 billon in 2008. Novartis is one of the largest healthcare companies in the world and a leading giant among pharmaceutical companies. Novartis produces medications for many diseases, cancer and cardiovascular medications that make up the bulk of sales. These medications include blockbuster drugs Gleevec and Diovan, which will benefit people who are more susceptible to cancer or cardiovascular problems. In addition to their current drugs, Novartis has one of the strongest pipelines in the pharmaceutical industry, with over 50 new products set to premier in the next several years.

Novartis is different from any other major pharmaceutical company in that it also has a strong presence in the generic market. Sandoz – one of its divisions – brought in 18% of the company’s total sales in 2008. With $7.6 billion in annual sales, Sandoz is the largest generic manufacturer under a major pharmaceutical company. This investment in the generic market allows Novartis to be somewhat insulated from patent expiration. At the same time, however, the investment in generics may complicate Novarti+s’s stance towards patent issues since it has large stakes on both sides of the issue.

Novartis faces many of the challenges of other pharmaceutical companies, including issues surrounding patent expiration and FDA approval. In addition, there is growing pressure in the US and abroad to lower the price of medication. Again, some of these challenges may be buffered by Novartis’s position in the generics market.


Novartis (Bangladesh) Limited at a GlanceName of the Company:

Novartis (Bangladesh) Limited

Shareholders                          : Novartis AG, (Switzerland) (60%)

Bangladesh Government (by BCIC) (40%)

Head Office                            : House 50, Road 2/A, Dhanmondi R/A

Dhaka 1209, Bangladesh

Managing Director                 : Ashfaque ur Rahman

Year of establishment             : 1997

Started Operation                   : 1973 (as “Ciba Geigy”)

Industry                                  : Pharmaceuticals

Divisions                                 : Pharmaceuticals, Sandoz and Consumer Health

Distribution Centers               : 11 Distribution Centers Nationwide

Manufacturing Plant             : Tongi, Gazipur (with GMP standard & European Certification)

Total Employees                     : 1028 (June, 2009)

Position in the Industry          : 12th

Competitors                            : GlaxoSmithKline, Sanofe-Aventis

Sales (BD)                             : Tk. 1340.97 Million (2008)

Export Value                          : Tk. 1058 Million (2007)

Corporate Website        

1.2: objectives of the study:

The report “An Appraisal of Novartis (Bangladesh) Limited” intends to explore the organizational functions of Novartis (Bangladesh) Limited in contrast of the overall pharmaceutical industry. The objectives of this report can be explained as follow:

I. To present an overview and principle activities of Novartis (Bangladesh) Limited

II.To appraise the strategic role of pharmaceuticals industry

1.3: scopes and methodology of the study:

To do this study the “Observation” and “Interview” methodology have been used. I have practically observed most types of activities of the Marketing process. When ever any critical situation arose, I interviewed the concerned persons to clear that matter or to know more about it. The report was designed by the following steps:


1. Topic Selection

The topic of this report- “Functions of Novartis (Bangladesh) Limited in contrast of Pharmaceuticals industry”, was chosen with the objective to present a scenario of Novartis (Bangladesh) Limited in the light of pharmaceuticals industry. The preparation of this report has been initiated by generating ideas based on the basic requirements of the study. Ideas have been designed regarding the overall presentation of the report, its appropriate contents, relevant information sources and processes.

2. Research Method

In the second stage, few concepts have been developed for the research procedures. The method for this study was simply collecting data from relevant sources (Basically from the history of Novartis (Bangladesh) Limited and direct interview from the respective product/portfolio managers, Key accounts Managers) and analyze them to generate relevant report. And the statistical data were processed on MS Excel.

3. Source of Information:

º  Primary Data:

Interview:A significant amount of information was collected through interviewing the Portfolio Managers (Marketing) and the Key Account Manager (Sales). All the officials were very much cooperative and provided in-depth knowledge about the working process.

Sample Size:To collect the relevant information, I have interviewed our KAM (Key Accounts Manager) and 7 product managers from both Pharma and Sandoz division. Although most of the information were collected from secondary source for the sake of this report.

Questions Asked:Because my report topic was based on the functions of Novartis (Bangladesh) Limited, most of the experiences I have gathered by observing the operations myself. That’s why no formal questioner was developed. But the factors I covered as my query were-

  • Divisional activities
  • Responsibilities of product managers
  • Production size of different divisions
  • Sales volume of each division

Based on these issues my report has proceeded.

Data YearsThe years I have focused to collect data was 2004 to 2008. But some of the information has been collected from the establishment years also.

Active Participation: Some information was collected from the active participation in different projects and assignments during the internship period. It was very much educative and provided quality experience to deal with practical problems.

Observation: Some information was collected on the basis of close observation of the processes and activities.

Secondary Data:

The secondary data were collected from the both the Global and local websites of Novartis and from its subsidiaries. Some additional information has been collected from various sources like Bangladesh Pharmaceutical Index, IMS (Information of Medical Statistics), annual reports, Internet, newspapers and features in different e-magazines.

4. Analysis and evaluation of the information

After all the information is collected, different types of analysis were done to provide a better understanding of the overview, trends and findings. Further evaluation was done to make sure that the analyses were feasible and relevant to the requirement of the report.

The final report writing has been initiated after the above processes are fully completed.

1.3: Limitations of the study:

There are few limitations of this report for which the findings of the study may not represent the complete scenario of the positioning activities. The limitations are summarized below:

  •  The Marketing and Finance Departments are core units of the Pharma division of Novartis. So most of the information is confidential and is not communicable publicly.
  •  Most of the tasks of this unit involve negotiating with the third parties (Clients) which require being an employee of Novartis Pharmaceuticals. So, as an Internee, I could not participate in those activities directly, I just had the basic concepts from interviewing.Novartis (Bangladesh) Limited has three core divisions working in Bangladesh i.e.
  • Pharmaceuticals (branded and patented products), Sandoz (generic products) and Consumer Health. As the Internship was performed in the Pharmaceutical division, the strategies of the other two divisions were not included in this report.

In the following parts of this report, various aspects of Novartis (Bangladesh) Limited are illustrated and the full work flow of the Marketing department is described.

Related Entrepreneurship Development Paper: